Health Canada has approved a new treatment for adult patients with nasopharyngeal carcinoma, a type of throat cancer, according to the manufacturer of the drug.
BeOne Medicines, a global oncology company based in Switzerland, said Health Canada had granted its tislelizumab injection medication a notice of compliance. The drug will be sold under the brand name Tevimbra, according to a Dec. 23 company news release.
